Clinical Trial Update: Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated whether the [18F]-AV-45 PET scan (Florbetapir F-18) can distinguish Alzheimer's disease from cognitively normal individuals. Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Florbetapir F-18 (florbetapir F-18)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2012-07-26